Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surveillance of Using Novel free Radical scavenger, edaravone to Investigate Survival Effect for ALS patients in Japan

Next Previous
Trial Profile

Surveillance of Using Novel free Radical scavenger, edaravone to Investigate Survival Effect for ALS patients in Japan

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms SUNRISE
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 01 Dec 2021 According to a Mitsubishi Tanabe Pharma America media release, data from this trial will be presented as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND by Kenta Yoshimura in Dec 2021.
    • 03 Dec 2020 According to a Mitsubishi Tanabe Pharma America media release, data from this trial will be presented as part of the Motor Neurone Disease Association (MNDA) 31st International Symposium on ALS/MND.
    • 18 Apr 2019 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top